AI-driven precision-oncology analysis identifies patient subtypes with potential enhanced response to glufosfamide Accepted ASCO abstract, submitted in collaboration with Eleison Pharmaceuticals, ...

The Next 100 Years to provide details about the company's recent performance, long-term outlook and strong position to deliver profitable growth and shareholder ...

Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs ...

Fujifilm has launched its Apeos multifunction printer (MFP) range in South Africa, engineered for demanding A3 and A4 office ...

Relevance, delivering best-in-class AI-search and generative experiences that maximize business outcomes at every point-of-experience, today announced that it has achieved ISO/IEC 27701 certification ...

Third quarter 2025 GAAP diluted earnings per share (EPS) of $2.64 and adjusted EPS of $3.26, an increase of 11% constant currency. Third quarter 2025 GAAP revenue of $2.01 billion ...

NXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosing NXP900 clinical drug-drug ...

Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor programMutant selective JAK2V617F JH2 inhibitors ...

Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment ...

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...

Uniti Solutions contributed $135.7 million of revenues and $72.2 million of contribution margin for the third quarter of 2025, achieving margins of approximately 53%. Uniti Solutions’ net capital ...

The 35th Performance Days in Munich saw record attendance. The trade fair presented innovations in performance textiles, ...